Leponex

Clozapine, the active ingredient in Leponex, is a atypical antipsychotic presented as a tablet for oral use. It treats treatment‑resistant schizophrenia, schizoaffective disorder and helps reduce suicidal behavior in patients with schizophrenia.

GNH USA supplies Leponex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leponex (clozapine) is used in the management of several serious psychiatric conditions.

- Treatment‑resistant schizophrenia: improves symptoms in patients who have not responded to other antipsychotics. - Schizoaffective disorder: reduces both psychotic and mood symptoms. - Reduction of suicidal behavior in patients with schizophrenia: lowers the risk of suicide.

Leponex may cause a variety of adverse reactions, ranging from common to serious.

Common Side Effects: - Sedation or drowsiness. - Weight gain. - Excessive salivation. - Constipation.

Serious or Rare Side Effects: - Agranulocytosis (dangerously low white‑blood‑cell count). - Myocarditis or cardiomyopathy. - Seizures, especially at higher plasma levels. - Orthostatic hypotension.

Before initiating therapy, several safety considerations are required.

- Blood monitoring: perform regular white‑blood‑cell counts due to risk of agranulocytosis. - Dose titration: start low and increase gradually to minimise orthostatic hypotension. - Cardiac assessment: monitor for myocarditis, particularly early in treatment. - Seizure risk: avoid in patients with a history of seizures; monitor EEG if indicated. - Pregnancy and lactation: use only if benefits outweigh potential risks and after specialist consultation. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Clozapine interacts with several medicines that may alter its safety or effectiveness.

Major Interactions (Avoid): - Concomitant use with other myelosuppressive agents: may increase risk of severe neutropenia. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): can raise clozapine plasma levels, increasing toxicity risk. - High‑dose benzodiazepines: may enhance respiratory depression.

Moderate Interactions (Monitor Closely): - CYP1A2 inducers (e.g., smoking, carbamazepine): may reduce clozapine levels, requiring dose adjustment. - Anticholinergic drugs: can worsen constipation. - QT‑prolonging agents: may increase risk of cardiac arrhythmias.